Antiinfektive Therapie in der Intensivmedizin

Intensivpatienten sind in hohem Maße durch Infektionen gefährdet. Antibiotika sind für sie von essenzieller Bedeutung und häufiger notwendig als bei anderen Patienten. In dieser Übersichtsarbeit werden grundlegende Aspekte zur antiinfektiven Therapie bei kritisch kranken Patienten und eine Reihe konkreter Handlungsempfehlungen vorgestellt.

Schlüsselwörter

kritisch kranker Patient - antiinfektive Therapie - Infektion - Antibiotikaresistenz - therapeutisches Drug-Monitoring - Applikationsmodus - Extrakorporalverfahren

• Literatur

• 1 Vincent J-L, Sakr Y, Singer M. EPIC III Investigators. et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 2020; 323: 1478-1487
• 2 Mettler J, Simcock M, Sendi P. et al. Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. BMC Infect Dis 2007; 7: 21
• 3 Roberts JA, Paul SK, Akova M. et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis 2014; 58: 1072-1083
• 4 GERMAP 2015. Antibiotikaresistenz und -verbrauch. Zugriff am 19. Juni 2023 unter: https://www.bvl.bund.de/SharedDocs/Downloads/05_Tierarzneimittel/germap2015.pdf;jsessionid=A2538EC4CF1F27A821F763CE37025527.internet971?__blob=publicationFile&v=5
• 5 Remschmidt C, Schneider S, Meyer E. et al. Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI). Dtsch Arztebl Int 2017; 114: 858-865
• 6 De Oliveira DMP, Forde BM, Kidd TJ. et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev 2020; 33: e00181-19
• 7 AWMF. S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. Zugriff am 19. Juni 2023 unter: https://register.awmf.org/de/leitlinien/detail/092–001
• 8 Livermore DM. Minimising antibiotic resistance. Lancet Infect Dis 2005; 5: 450-459
• 9 Geffers C, Gastmeier P. Nosokomiale Infektionen und multiresistente Erreger in Deutschland. Epidemiologische Daten aus dem Krankenhaus-Infektions-Surveillance-System. Dtsch Arztebl Int 2011; 108: 87-93
• 10 AWMF. S1-Leitlinie: Diagnose und Therapie von Candida-Infektionen. AWMF-Register 082/005. 2020 Zugriff am 19. Juni 2023 unter: https://register.awmf.org/assets/guidelines/082–005l_S1_Diagnose-Therapie-Candida-Infektionen_2020–09.pdf
• 11 Sandiumenge A, Diaz E, Bode M. et al. Therapy of ventilator associated pneumonia. A patient-based approach on the ten rules of “The Tarragona Strategy”. Intensive Care Med 2003; 29: 876-883
• 12 Kumar A, Roberts D, Wood KE. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic schock. Crit Care Med 2006; 34: 1589-1596
• 13 Ferrer R, Martin-Loeches I, Phillips G. et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749-1755
• 14 Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A. et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40: 32-40
• 15 Pai Mangalore R, Ashok A, Lee SJ. et al. Beta-Lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis. Clin Infect Dis 2022; 75: 1848-1860
• 16 Trautmann M, Lepper P, Bodmann K-F. Resistenzentwicklung von Pseudomonas aeruginosa unter antibiotischer Therapie. Arzneimitteltherapie 2006; 24: 50-56
• 17 Beganovic M, Cusumano JA, Lopes V. et al. Comparative effectiveness of exclusive exposure to nafcillin or oxacillin, cefazolin, piperacillin/tazobactam, and fluoroquinolones among a national cohort of veterans with methicillin-susceptible Staphylococcus aureus bloodstream infection. Open Forum Infect Dis 2019; 6: ofz270
• 18 Reyes LF, Garcia E, Ibánez-Prada ED. et al. Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis. Crit Care 2023; 27: 212
• 19 Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011; 15: R267
• 20 Montravers P, Tubach F, Lescot T. et al. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial. Intensive Care Med 2018; 44: 300-310
• 21 Bernard L, Arvieux C, Brunschweiler B. et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med 2021; 384: 1991-2001
• 22 de Jonge NA, Sikkens JJ, Zweegman S. et al. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. Lancet Haematol 2022; 9: e563-e572
• 23 Fugit RV, McCoury JBM, Bessesen MT. Procalcitonin for sepsis management: Implementation within an antimicrobial stewardship program. Am J Health Syst Pharm 2023; 80 (Suppl. 2) S49-S54
• 24 Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51
• 25 Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev 2014; 27: 68-88
• 26 Thallinger C, Buerger C, Plock N. et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008; 61: 173-176
• 27 Alobaid AS, Brinkmann A, Frey OR. et al. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. J Antimicrob Chemother 2016; 71: 696-702
• 28 Udy AA, Lipman J, Jarrett P. et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. Crit Care 2015; 19: 28
• 29 Roberts JA, Udy AA, Jarrett P. et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. J Antimicrob Chemother 2015; 70: 1495-1502
• 30 Hagel S, Bach F, Brenner T. et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med 2022; 48: 311-321
• 31 Klimek L, Merk HF, Dickel H. et al. Vermutete Penicillinallergie: De-Labeling als wichtige Aufgabe für das Antibiotika-Stewardship. Dtsch Arztebl Ausg A 2022; 119: A868-871
• 32 Cianferoni S, Devigili A, Ocampos-Martinez E. et al. Development of acute kidney injury during continuous infusion of vancomycin in septic patients. Infection 2013; 41: 811-820
• 33 Dulhunty JM, Roberts JA, Davis JS. et al. A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am J Respir Crit Care Med 2015; 192: 1298-1305
• 34 Abdul-Aziz MH, Sulaiman H, Mat-Nor MB. et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 2016; 42: 1535-1545
• 35 Roberts JA, Joynt GM, Lee A. et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study. Clin Infect Dis 2021; 72: 1369-1378
• 36 Schneider AG, André P, Scheier J. et al. Pharmacokinetics of antiinfective agents during CytoSorb hemoadsorption. Sci Rep 2021; 11: 10493